File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Intralesional triamcinolone acetonide injection for the treatment of primary chalazions

TitleIntralesional triamcinolone acetonide injection for the treatment of primary chalazions
Authors
Issue Date2014
Citation
International Ophthalmology, 2014, v. 34 n. 5, p. 1049-1053 How to Cite?
AbstractThe aim of this study was to investigate the safety and efficacy of intralesional triamcinolone acetonide (TA) injection in the treatment of primary chalazions not responding to conservative treatment. Patient medical records were retrospectively reviewed for all consecutive patients that received intralesional TA injection by a single surgeon between January 2012 and March 2013 for the treatment of unresolved primary chalazions despite 1 month of conservative treatment. The dose of TA injection ranged from 2 to 6 mg (40 mg/mL) depending on the size of the chalazion. The main outcome measures included time to resolution, time to 50 % size reduction, and complications from the treatment. During the study period, 48 chalazions from 38 patients were treated by intralesional TA injection. A 50 % reduction in size was achieved in 81.3 % of chalazions in 4 weeks and 83 % achieved complete resolution in 6 weeks. The mean time to complete resolution was 15.7 +/- 10.0 days. There were no complications noted from the injections; 14.6 % required subsequent incision and curettage and 2.1 % required a second TA injection for complete resolution. Intralesional TA injection is a safe, simple, and effective procedure for the management of primary chalazions and may be considered as an alternative to incision and curettage in cases not responding to conservative treatment.
Persistent Identifierhttp://hdl.handle.net/10722/208477
ISSN
2015 SCImago Journal Rankings: 0.526

 

DC FieldValueLanguage
dc.contributor.authorWong, MYen_US
dc.contributor.authorYau, GSen_US
dc.contributor.authorLee, WYJen_US
dc.contributor.authorYuen, CYen_US
dc.date.accessioned2015-03-11T07:06:16Z-
dc.date.available2015-03-11T07:06:16Z-
dc.date.issued2014en_US
dc.identifier.citationInternational Ophthalmology, 2014, v. 34 n. 5, p. 1049-1053en_US
dc.identifier.issn1573-2630en_US
dc.identifier.urihttp://hdl.handle.net/10722/208477-
dc.description.abstractThe aim of this study was to investigate the safety and efficacy of intralesional triamcinolone acetonide (TA) injection in the treatment of primary chalazions not responding to conservative treatment. Patient medical records were retrospectively reviewed for all consecutive patients that received intralesional TA injection by a single surgeon between January 2012 and March 2013 for the treatment of unresolved primary chalazions despite 1 month of conservative treatment. The dose of TA injection ranged from 2 to 6 mg (40 mg/mL) depending on the size of the chalazion. The main outcome measures included time to resolution, time to 50 % size reduction, and complications from the treatment. During the study period, 48 chalazions from 38 patients were treated by intralesional TA injection. A 50 % reduction in size was achieved in 81.3 % of chalazions in 4 weeks and 83 % achieved complete resolution in 6 weeks. The mean time to complete resolution was 15.7 +/- 10.0 days. There were no complications noted from the injections; 14.6 % required subsequent incision and curettage and 2.1 % required a second TA injection for complete resolution. Intralesional TA injection is a safe, simple, and effective procedure for the management of primary chalazions and may be considered as an alternative to incision and curettage in cases not responding to conservative treatment.en_US
dc.languageengen_US
dc.relation.ispartofInternational Ophthalmologyen_US
dc.titleIntralesional triamcinolone acetonide injection for the treatment of primary chalazionsen_US
dc.typeArticleen_US
dc.identifier.emailLee, WYJ: jackylee@hku.hken_US
dc.identifier.authorityLee, WYJ=rp01498en_US
dc.identifier.doi10.1007/s10792-014-9904-1en_US
dc.identifier.pmid24442761-
dc.identifier.scopuseid_2-s2.0-84892384097-
dc.identifier.volume34en_US
dc.identifier.issue5en_US
dc.identifier.spage1049en_US
dc.identifier.epage1053en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats